Opus Genetics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Opus Genetics (IRD).

Price Target Range — 7 Quarters

Analyst Consensus — 16 Analysts

1S.Buy

15Buy

Consensus RatingBuy# Analysts16Avg. Consensus PT$11Upside to Avg. PT+124.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 10, 2026	Wedbush	Yun Zhong	PT Raise	Outperform	$10→$13
Sep 9, 2026	Chardan Capital	Andreas Argyrides	PT Raise	Buy	$13→$16
Sep 9, 2026	Oppenheimer	Andreas Argyrides	PT Raise	Outperform	$10→$20
Sep 9, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$8
Sep 9, 2026	BTIG	Thomas Shrader	Maintained	Buy	$12
Aug 7, 2026	RBC Capital	Lisa Walter	PT Cut	Outperform	$10→$9
Jul 29, 2026	TD Cowen	Ritu Baral	Initiate	Buy	—
Jul 6, 2026	Chardan Capital	Andreas Argyrides	Maintained	Buy	$13
Jul 6, 2026	BTIG	Thomas Shrader	Maintained	Buy	$12
Jun 18, 2026	Chardan Capital	Andreas Argyrides	PT Raise	Buy	$11→$13
Jun 17, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$8
Jun 16, 2026	BTIG	Thomas Shrader	Maintained	Buy	$12
Jun 15, 2026	Citizens	Jonathan Wolleben	Maintained	Market Outperform	$11
Jun 4, 2026	Guggenheim	Debjit Chattopadhyay	Initiate	Buy	$16
May 21, 2026	Leerink Partners	Lili Nsongo	Initiate	Outperform	$10
May 13, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$12→$11
Apr 28, 2026	Citizens	Jonathan Wolleben	Initiate	Market Outperform	$12
Mar 30, 2026	Cantor Fitzgerald	Steve Seedhouse	Initiate	Overweight	$15
Mar 16, 2026	Oppenheimer	Andreas Argyrides	Initiate	Outperform	$10
Mar 12, 2026	Wedbush	Yun Zhong	PT Raise	Outperform	$8→$10

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13

Wedbush analyst Yun Zhong maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $13.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20

Oppenheimer analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $20.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target

BTIG analyst Thomas Shrader reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $12 price target.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9

RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and lowers the price target from $10 to $9.

Benzinga Newsdesk

PRO
TD Cowen Initiates Coverage On Opus Genetics with Buy Rating

TD Cowen analyst Ritu Baral initiates coverage on Opus Genetics (NASDAQ:IRD) with a Buy rating.

Benzinga Newsdesk

Opus Genetics Inc

Opus Genetics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13

PRO
Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20

PRO
HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target

PRO
BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target

PRO
RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9

PRO
TD Cowen Initiates Coverage On Opus Genetics with Buy Rating

People Also Watch

People Also Watch

Opus Genetics Inc

Opus Genetics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13

PROOppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20

PROHC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target

PROBTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target

PRORBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9

PROTD Cowen Initiates Coverage On Opus Genetics with Buy Rating

People Also Watch

People Also Watch

PRO
Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13

PRO
Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20

PRO
HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target

PRO
BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target

PRO
RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9

PRO
TD Cowen Initiates Coverage On Opus Genetics with Buy Rating